Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.8.0.1
Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
 9 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Finite-lived Intangible Assets, Accumulated Amortization $ (9,701,000) $ (7,262,000)
Finite-lived Intangible Assets, Net Carrying Value $ 33,919,000 36,358,000
Diagnostic Assets, Thyroid [Member] | Asuragen Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years  
Finite-lived Intangible Assets, gross $ 8,519,000 8,519,000
Diagnostic Assets, Pancreas Test [Member] | RedPath Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 7 years  
Finite-lived Intangible Assets, gross $ 16,141,000 16,141,000
Diagnostic Assets, Barrett's Test [Member] | RedPath Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years  
Finite-lived Intangible Assets, gross $ 18,351,000 18,351,000
Diagnostic Lab, CLIA Lab [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 2 years 3 months 19 days  
Finite-lived Intangible Assets, Net Carrying Value $ 609,000 609,000
Diagnostic Assets [Member]    
Finite-lived Intangible Assets, gross $ 43,011,000 $ 43,011,000